Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.40 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | CDC25B | P30305 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | PTPRC | P08575 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725425 | 0.86 | MEN1 (0.45) | EHMT2EHMT1MEN1KMT2ACDC25B | |
| SCHEMBL7315832 | 0.76 | ALDH1A1 (0.50) | MEN1KMT2AMAPTPOLBKDM4E | |
| SCHEMBL223194 | 0.75 | IDO1 (0.48) | EHMT2EHMT1MEN1KMT2ACDC25B | |
| SCHEMBL3307260 | 0.70 | MEN1 (0.39) | EHMT2EHMT1MEN1KMT2ACDC25B | |
| SCHEMBL28560306 | 0.68 | MEN1 (0.41) | EHMT2EHMT1MEN1KMT2ACDC25B | |
| SCHEMBL3103996 | 0.67 | MEN1 (0.33) | EHMT2EHMT1MEN1KMT2ACDC25B | |
| SCHEMBL20483611 | 0.67 | MEN1 (0.37) | EHMT2EHMT1MEN1KMT2ACDC25B | |
| SCHEMBL2095985 | 0.64 | KMT2A (0.50) | EHMT2EHMT1MEN1KMT2ACDC25B | |
| SCHEMBL110858 | 0.61 | — | — | |
| SCHEMBL216271 | 0.60 | MAOA (0.42) | EHMT2EHMT1MEN1KMT2ACDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113423709-B | Triazinone imidazole compound and medical application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2020207352-A1 | TRIAZINE BENZIMIDAZOLE COMPOUNDS AND MEDICAL USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2020-10-15 | — | — | WO | disclosed |
| US-9296697-B2 | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors | ABBOTT LABORATORIES (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2606351-A1 | IN-SITU REAGENT FOR DETECTION OF PROTEINS | Queen Mary & Westfield College, University of London (GB) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012022945-A1 | IN-SITU REAGENT FOR DETECTION OF PROTEINS | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2012-02-23 | — | — | WO | disclosed |
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-1490047-B1 | CERTAIN PHARMACEUTICALLY USEFUL SUBSTITUTED AMINOALKYL HETEROCYCLES | SMITHKLINE BEECHAM CORP (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | PALAU PHARMA, S.A. (ES) | 2009-12-10 | — | — | US | disclosed |
| US-7560586-B2 | Acid and ester compounds and methods of using the same | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1511483-A4 | METHODS OF TREATMENT WITH LXR MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2005023247-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023196-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-1511483-A2 | METHODS OF TREATMENT WITH LXR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2005013946-A2 | METHODS OF TREATMENT INFLAMMATORY BOWEL WITH LXR AGONISTS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005009383-A2 | METHODS OF TREATMENT WITH LXR AGONISTS | GLAXO GROUP LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| EP-1497270-A1 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SmithKline Beecham Corporation (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1487776-A1 | ACID AND ESTER COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004043939-A1 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003082802-A1 | ACID AND ESTER COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082198-A2 | METHODS OF TREATMENT WITH LXR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | HRH4, HRH2, HRH3 | EHMT2 212/4885EHMT1 404/4885MEN1 3414/4885 |
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | HTR5A, HTR2C, HTR1E | EHMT2 2686/4885EHMT1 3040/4885MEN1 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.